Updated:
Will the FDA approve the new monoclonal antibody drug for the treatment of Alzheimer's disease?
Prediction market for: Will the FDA approve the new monoclonal antibody drug for the treatment of Alzheimer's disease?
- Volume
- 52 USDT
- Participants
- 2
- Status
- Open
- Market closes
About the event
A forecast on whether the new drug for the treatment of Alzheimer's disease will be approved.
Outcomes and probabilities
- The FDA will approve the new monoclonal antibody drug for the treatment of Alzheimer's disease.17%
- The FDA will not approve the new monoclonal antibody drug for the treatment of Alzheimer's disease.83%
Probabilities reflect participant positions and do not guarantee the event's outcome.
Related markets
- Will Donald Trump live until the end of October 2026?
- Will the Second Coming of Christ happen in October?
- Will @aaxamit reach 15 million views?
- Threads user @tebechonada won't find a husband until February
- Will a plague pandemic be declared?
- Will there be 100,000 users in Winion by the end of summer 2026?
- Will Angelina release 3 videos on her blog by the end of 2026?
- Will the FDA approve the new pancreatic cancer drug?
Questions about this market
- When does this market close?
- Will the FDA approve the new monoclonal antibody drug for the treatment of Alzheimer's disease? — October 20, 2026 at 8:00 PM UTC.
- Which outcomes are available?
- The FDA will approve the new monoclonal antibody drug for the treatment of Alzheimer's disease. · The FDA will not approve the new monoclonal antibody drug for the treatment of Alzheimer's disease.